Belotti D - Search Results

1

Thrombospondin-1 in drug activity and tumor response to therapies.

Longhi E, Carminati L, Carlessi E, Belotti D, Taraboletti G. Longhi E, et al. Among authors: belotti d. Semin Cell Dev Biol. 2024 Mar 1;155(Pt B):45-51. doi: 10.1016/j.semcdb.2023.06.009. Epub 2023 Jul 4. Semin Cell Dev Biol. 2024. PMID: 37414720 Review.

2

Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells.

Taraboletti G, Belotti D, Giavazzi R. Taraboletti G, et al. Among authors: belotti d. EXS. 1992;61:210-3. doi: 10.1007/978-3-0348-7001-6_32. EXS. 1992. PMID: 1617233

3

Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.

Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R. Taraboletti G, et al. Among authors: belotti d. J Natl Cancer Inst. 1995 Feb 15;87(4):293-8. doi: 10.1093/jnci/87.4.293. J Natl Cancer Inst. 1995. PMID: 7535861

4

Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene.

Taraboletti G, Belotti D, Dejana E, Mantovani A, Giavazzi R. Taraboletti G, et al. Among authors: belotti d. Cancer Res. 1993 Aug 15;53(16):3812-6. Cancer Res. 1993. PMID: 8393382

5

Enhancement of metastatic potential of murine and human melanoma cells by laminin receptor peptide G: attachment of cancer cells to subendothelial matrix as a pathway for hematogenous metastasis.

Taraboletti G, Belotti D, Giavazzi R, Sobel ME, Castronovo V. Taraboletti G, et al. Among authors: belotti d. J Natl Cancer Inst. 1993 Feb 3;85(3):235-40. doi: 10.1093/jnci/85.3.235. J Natl Cancer Inst. 1993. PMID: 8423629

6

The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor.

Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, Giavazzi R. Taraboletti G, et al. Among authors: belotti d. Cell Growth Differ. 1997 Apr;8(4):471-9. Cell Growth Differ. 1997. PMID: 9101093

7

Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.

Belotti D, Rieppi M, Nicoletti MI, Casazza AM, Fojo T, Taraboletti G, Giavazzi R. Belotti D, et al. Clin Cancer Res. 1996 Oct;2(10):1725-30. Clin Cancer Res. 1996. PMID: 9816123

8

The microtubule-affecting drug paclitaxel has antiangiogenic activity.

Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. Belotti D, et al. Clin Cancer Res. 1996 Nov;2(11):1843-9. Clin Cancer Res. 1996. PMID: 9816139

9

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R. Manenti L, et al. Among authors: belotti d. Eur J Cancer. 2003 Sep;39(13):1948-56. doi: 10.1016/s0959-8049(03)00427-1. Eur J Cancer. 2003. PMID: 12932675 Clinical Trial.

10

Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Belotti D, et al. Cancer Res. 2003 Sep 1;63(17):5224-9. Cancer Res. 2003. PMID: 14500349

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page